ASCO 2017: highlights in breast cancer
Author:
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://link.springer.com/article/10.1007/s12254-017-0368-7/fulltext.html
Reference17 articles.
1. Schneeweiss A, Moebus V, Tesch H, et al. A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol. 2017;35(suppl):abstr 518.
2. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56.
3. Geyer CE, O’Shaughnessy J, Untch M, et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). J Clin Oncol. 2017;35(suppl):abstr 520.
4. Loibl S, Werutsky G, Nekljudova V, et al. Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. J Clin Oncol. 2017;35(suppl):abstr 571.
5. Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017;35(suppl):abstr 1008.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer;Frontiers in Oncology;2023-10-18
2. Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer;PLOS ONE;2022-06-24
3. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up;European Journal of Surgical Oncology;2021-04
4. DNA Damage Repair Inhibitor for Breast Cancer Treatment;Advances in Experimental Medicine and Biology;2021
5. Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review;BMC Cancer;2020-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3